Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. More Details
No risks detected for TARO from our risk checks.
Flawless balance sheet with moderate growth potential.
Share Price & News
How has Taro Pharmaceutical Industries's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: TARO is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: TARO's weekly volatility (3%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: TARO matched the US Pharmaceuticals industry which returned 11.4% over the past year.
Return vs Market: TARO underperformed the US Market which returned 51.8% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Taro Pharmaceutical Industries's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 months ago | Simply Wall StA Look At Taro Pharmaceutical Industries' (NYSE:TARO) Share Price Returns
6 months ago | Simply Wall StHow Many Taro Pharmaceutical Industries Ltd. (NYSE:TARO) Shares Do Institutions Own?
8 months ago | Simply Wall StA Look At The Intrinsic Value Of Taro Pharmaceutical Industries Ltd. (NYSE:TARO)
Is Taro Pharmaceutical Industries undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: TARO ($75.47) is trading above our estimate of fair value ($1.6)
Significantly Below Fair Value: TARO is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: TARO is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.
PE vs Market: TARO is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate TARO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: TARO is good value based on its PB Ratio (1.6x) compared to the US Pharmaceuticals industry average (3.6x).
How is Taro Pharmaceutical Industries forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TARO is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: TARO is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: TARO's is expected to become profitable in the next 3 years.
Revenue vs Market: TARO's revenue (3.6% per year) is forecast to grow slower than the US market (9.2% per year).
High Growth Revenue: TARO's revenue (3.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if TARO's Return on Equity is forecast to be high in 3 years time
How has Taro Pharmaceutical Industries performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: TARO is currently unprofitable.
Growing Profit Margin: TARO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: TARO is unprofitable, and losses have increased over the past 5 years at a rate of 41.3% per year.
Accelerating Growth: Unable to compare TARO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TARO is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (9.6%).
Return on Equity
High ROE: TARO has a negative Return on Equity (-18.13%), as it is currently unprofitable.
How is Taro Pharmaceutical Industries's financial position?
Financial Position Analysis
Short Term Liabilities: TARO's short term assets ($1.5B) exceed its short term liabilities ($584.1M).
Long Term Liabilities: TARO's short term assets ($1.5B) exceed its long term liabilities ($37.2M).
Debt to Equity History and Analysis
Debt Level: TARO is debt free.
Reducing Debt: TARO had no debt 5 years ago.
Debt Coverage: TARO has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: TARO has no debt, therefore coverage of interest payments is not a concern.
What is Taro Pharmaceutical Industries's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate TARO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate TARO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if TARO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TARO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of TARO's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Uday Baldota (50 yo)
Mr. Uday V. Baldota has been Director at Association for Accessible Medicines. He has been the Chief Executive Officer of Taro Pharmaceutical Industries Ltd. since August 28, 2017 and served as its Co-Chie...
Experienced Management: TARO's management team is seasoned and experienced (8.2 years average tenure).
Experienced Board: TARO's board of directors are considered experienced (6.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Taro Pharmaceutical Industries Ltd.'s company bio, employee growth, exchange listings and data sources
- Name: Taro Pharmaceutical Industries Ltd.
- Ticker: TARO
- Exchange: NYSE
- Founded: 1959
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$2.873b
- Shares outstanding: 38.26m
- Website: https://www.taro.com
Number of Employees
- Taro Pharmaceutical Industries Ltd.
- 14 Hakitor Street
- Haifa Bay
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Isra...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/07 22:45|
|End of Day Share Price||2021/05/07 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.